<DOC>
	<DOCNO>NCT00000655</DOCNO>
	<brief_summary>To evaluate effectiveness atovaquone ( 566C80 ) compare standard antipneumocystis agent , ( SMX/TMP ) , treatment mild moderate Pneumocystis carinii pneumonia ( PCP ) AIDS patient . To compare safety short-term ( 21 day ) treatment 566C80 SMX/TMP AIDS patient acute episode PCP . Standard therapies acute treatment PCP involve either SMX/TMP pentamidine isetionate . Although treatment equally effective , side effect prevent completion therapy 11-55 percent patient .</brief_summary>
	<brief_title>A Randomized , Double-Blind Study 566C80 Versus Septra ( Sulfamethoxazole/Trimethoprim ) Treatment Pneumocystis Carinii Pneumonia AIDS Patients</brief_title>
	<detailed_description>Standard therapy acute treatment PCP involve either SMX/TMP pentamidine isetionate . Although treatment equally effective , side effect prevent completion therapy 11-55 percent patient . Patients randomize one two treatment group receive either ( 1 ) 566C80 21 day , ( 2 ) SMX/TMP 21 day . Patients stratify accord severity PCP . Group A arterial-alveolar ( A-a ) DO2 &lt; 35 mm Hg . Group B A-a DO2 35-45 mm Hg. , also require receive therapy Corticosteroids . All dose take food . During 21 day treatment , patient examine clinically adverse effect hematology ( blood-related ) clinical chemistry study conduct minimum 2 time weekly . More frequent monitoring may require discretion investigator . To evaluate effectiveness study medication , clinical status patient evaluate 2 3 time per week ( e.g. , dyspnea score , cough score , chest tightness/pain score , vital sign ) . Also , day 7 21 treatment , arterial blood gas measurement chest X-ray performed . Patients experience severe toxicity discontinue study place alternative therapy . Patients also remove study show significant clinical deterioration within first 7 day therapy improvement 10 day therapy . This study involve double placebo one group randomize receive oral 566C80 placebo tablet look like SMX/TMP group receive SMX/TMP placebo tablet look like 566C80 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<criteria>Inclusion Criteria Patient must follow : Presumptive diagnosis AIDS define CDC . Untreated Pneumocystis carinii pneumonia ( PCP ) . Willingness ability give inform consent . Prior Medication : Allowed : Prophylactic therapy Pneumocystis carinii pneumonia ( PCP ) include aerosolize pentamidine sulfamethoxazole/trimethoprim ( SMX/TMP ) ( dose great two DS tablet twice daily ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Judged investigator impend respiratory failure . Malabsorption vomit would , judgment investigator , potentially limit retention absorption oral therapy . Concurrent bacterial , fungal , viral pneumonitis , pulmonary Kaposi 's sarcoma concurrent illness , chronic pulmonary disease , investigator 's opinion , would make interpretation drug efficacy difficult . Concurrent Medication : Excluded : Corticosteroid treatment ( except replacement therapy patient Group B ) . Ganciclovir . Zidovudine ( AZT ) . Investigational agent include antiretroviral agent ( didanosine ( ddI ) , dideoxycytidine ( ddC ) , etc. ) . Drugs likely antipneumocystis effect : Sulfonamides . Pentamidine . Dapsone . Trimethoprim . Other DHFR inhibitor . Primaquine . Clindamycin . Sulfonylureas . Patients follow exclude : Judged investigator impend respiratory failure . Prior therapy episode PCP treatment within 4 week entry prior episode PCP . Unable refuse discontinue zidovudine , ganciclovir , antiretroviral agent 21 day treatment period . Unable take medication orally unwilling unable take study medication food . Significant psychosis emotional disorder , investigator 's opinion , patient would compliant study protocol . Prior document glucose6phosphate dehydrogenase ( G6PD ) deficiency . Prior history lifethreatening toxicity SMX/TMP severe rash StevensJohnson syndrome . Prior Medication : Excluded : Prior therapy episode Pneumocystis carinii pneumonia ( PCP ) treatment within 4 week prior episode PCP . Blood transfusion .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Naphthoquinones</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>